[2-(2-Chlorophenyl)phenyl]methanol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [2-(2-Chlorophenyl)phenyl]methanol
• 化学式: C₁₃H₁₁ClO
• 分子量: 218.683
• InChiKey: FCMVFAXBBGSVRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  [2-(2-Chlorophenyl)phenyl]methanol 在 potassium tert-butylate 作用下， 以 二甲基亚砜 为溶剂， 反应 3.0h， 以82%的产率得到6H-苯并[c]苯并吡喃
  参考文献：
  名称：

  KO^tBu mediated efficient approach for the synthesis of fused heterocycles via intramolecular O-/N-arylations

  摘要：

  KOtBu介导的高效方法已被开发用于合成6H-苯并[c]色酮，6H-苯并[c]色酮-6-酮，咔唑，二苯并呋喃和二苯并氧杂环戊二烯。

  DOI：

  10.1039/c5ra07532g

文献信息

• [EN] CHIRAL TERTIARY AMINOALKYLNAPHTHOLS<br/>[FR] AMINOALKYLNAPHTOLS CHIRAUX TERTIAIRES
  申请人：UNIV HONG KONG POLYTECHNIC

  公开号：WO2005087707A1

  公开（公告）日：2005-09-22

  The invention relates to the compounds of formula: (I) which are as defined in the specification. Their use as chiral ligands in catalytic aryl transfer reactions to aromatic aldehydes is also described.

  该发明涉及以下化合物的公式：(I)，其在说明书中定义。还描述了它们作为手性配体在催化芳基转移反应中对芳香醛的使用。
• [EN] NOCICEPTIN RECEPTOR ORL-1 AGONISTS FOR USE IN TREATING COUGH<br/>[FR] AGONISTES DU RECEPTEUR ORL-1 DE LA NOCICEPTINE UTILISES POUR LE TRAITEMENT DE LA TOUX
  申请人：SCHERING CORP

  公开号：WO2001007050A1

  公开（公告）日：2001-02-01

  The present invention relates to the use of ORL-1 receptor agonists for the treatment of cough, alone or in combination with one or more agents for the treatment of cough, allergy or asthma symptoms, in particular to the use of ORL-1 agonists of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: the dotted line represents and optional double bond; X1 is optionally substituted alkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl; X2 is-CHO, -CN, optionally substituted amino, alkyl, or aryl; or X1 is optionally substituted benzofused heterocyclyl and X2 is hydrogen; or X?1 and X2¿ together form an optionally benzofused spiro heterocyclyl group R?1, R2, R3 and R4¿ are independently H and alkyl, or (R?1 and R4) or (R2 and R3) or (R1 and R3) or (R2 and R4¿) together can form an alkylene bridge of 1 to 3 carbon atoms; Z1 is optionally substituted alkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, or -CO¿2?(alkyl or substituted amino) or CN; Z?2¿ is H or Z1; Z3 is H or alkyl; or Z?1, Z2 and Z3¿, together with the carbon to which they are attached, form bicyclic saturated or unsaturated rings.

  本发明涉及使用ORL-1受体激动剂治疗咳嗽，单独或与一种或多种用于治疗咳嗽、过敏或哮喘症状的药物组合使用，特别是使用式（I）的ORL-1激动剂或其药学上可接受的盐或溶剂，其中：虚线代表可选的双键；X1是可选的取代基的烷基、环烷基、芳基、杂芳基或杂环烷基；X2是-CHO、-CN、可选的取代氨基、烷基或芳基；或X1是可选的取代苯并杂环基，X2是氢；或X1和X2一起形成可选的苯并螺杂环基团；R1、R2、R3和R4独立地为H和烷基，或（R1和R4）或（R2和R3）或（R1和R3）或（R2和R4）一起形成1至3个碳原子的烷基桥；Z1是可选的取代基的烷基、芳基、杂芳基、环烷基或杂环烷基，或-CO2（烷基或取代氨基）或-CN；Z2是H或Z1；Z3是H或烷基；或Z1、Z2和Z3，与它们连接的碳一起，形成二环饱和或不饱和环。
• [EN] HIGH AFFINITY LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1<br/>[FR] LIGANDS D'AFFINITE ELEVEE POUR RECEPTEUR DE LA NOCICEPTINE ORL-1
  申请人：SCHERING CORP

  公开号：WO2000006545A1

  公开（公告）日：2000-02-10

  Compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: the dotted line represents an optional double bond; X1 is optionally substituted alkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl; X2 is -CHO, -CN, optionally substituted amino, alkyl, or aryl; or X1 is optionally substituted benzofused heterocyclyl and X2 is hydrogen; or X?1 and X2¿ together form an optionally benzofused spiro heterocyclyl group; R?1, R2, R3 and R4¿ are independently H and alkyl, or (R?1 and R4) or (R2 and R3) or (R1 and R3) or (R2 and R4¿) together can form an alkylene bridge of 1 to 3 carbon atoms; Z1 is optionally substituted alkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, or -CO¿2?(alkyl or substituted amino) or CN; Z?2¿ is H or Z1; Z3 is H or alkyl; or Z?1, Z2 and Z3¿, together with the carbon to which they are attached, form bicyclic saturated or unsaturated rings; pharmaceutical compositions therefore, and the use of said compounds as nociceptin receptor inhibitors useful in the treatment of pain, anxiety, cough, asthma, depression and alcohol abuse are disclosed.

  化合物的化学式为（I），或其药学上可接受的盐或溶剂，其中：虚线代表可选的双键；X1为可选取代的烷基，环烷基，芳基，杂芳基或杂环烷基；X2为-CHO，-CN，可选取代的氨基，烷基或芳基；或X1为可选取代的苯并杂环烷基，X2为氢；或X1和X2共同形成可选取代的苯并螺环杂环烷基；R1，R2，R3和R4分别为H和烷基，或（R1和R4）或（R2和R3）或（R1和R3）或（R2和R4）共同形成1到3个碳原子的烷基桥；Z1为可选取代的烷基，芳基，杂芳基，环烷基或杂环烷基，或-CO2（烷基或取代氨基）或-CN；Z2为H或Z1；Z3为H或烷基；或Z1，Z2和Z3共同与它们连接的碳形成螺环饱和或不饱和环；公开了药物组合物，以及将所述化合物用作痛觉受体抑制剂，有助于治疗疼痛，焦虑，咳嗽，哮喘，抑郁症和酗酒。
• Sulfonamide compounds and pharmaceutical use thereof
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US20040180947A1

  公开（公告）日：2004-09-16

  A sulfonamide compound of the formula (I): R 1 —SO 2 NHCO-A-X—R 2 (I) wherein R 1 is alkyl, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycylic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R 2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.

  化合物的分子式为（I）：R1—SO2NHCO-A-X—R2（I），其中R1为烷基，烯基，炔基等；A为可选取代的杂多环基团，但不包括苯并咪唑基，吲哚基，4,7-二氢苯并咪唑基和2,3-二氢苯并噁唑基；X为烷基，氧杂环基，氧杂环（较低）烷基等；R2为可选取代的芳基，取代联苯基等，其盐和含有该化合物的药物组合物。该磺酰胺化合物对于基于其降低血糖水平的活性，cGMP-PDE（特别是PDE-V）抑制活性，平滑肌松弛活性，支气管扩张活性，血管扩张活性，平滑肌细胞抑制活性和抗过敏活性可治疗的疾病具有有效性。
• Chiral Tertiary Aminoalkylnaphthols
  申请人：Chan Albert Sun-Chi

  公开号：US20080045757A1

  公开（公告）日：2008-02-21

  The invention relates to the compounds of formula: (I) which are as defined in the specification. Their use as chiral ligands in catalytic aryl transfer reactions to aromatic aldehydes is also described.

  本发明涉及化合物的公式：（I），其在规范中定义。还描述了它们作为手性配体在催化芳基转移反应中对芳香醛的使用。